At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 622 enrolled
Drug / intervention
DFN-15 Active +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Efficacy, Tolerability, and Safety Study of DFN-15 in Episodic Migraine With or Without Aura
In Brief
A Phase 3 clinical trial evaluating DFN-15 Active and DFN-15 Placebo for Migraine Headache. Completed, enrolled 622 participants across 45 sites.
Detailed Summary
Efficacy, Tolerability, and Safety of DFN-15 in episodic migraine with or without aura, being conducted at multiple centers in the United States.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMigraine Headache
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
2017201820192020202120222023202420252026
Enrollment StartDec 2016
First PostedDec 2016
Primary CompletionNov 2017
Study CompletionMay 2019
TodayJul 2026
First PostedDec 30, 2016
Enrollment StartDec 1, 2016
Primary CompletionNov 1, 2017
Study CompletionMay 1, 2019
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 9.5 years ago
Interventions
DFN-15 Activedrug
DFN-15 Placeboother